|Bid||223.75 x 100|
|Ask||233.79 x 100|
|Day's Range||222.05 - 225.19|
|52 Week Range||184.50 - 256.80|
|PE Ratio (TTM)||6.97|
|Dividend & Yield||2.80 (1.26%)|
|1y Target Est||N/A|
The US General Medicines segment reported revenues of $1.43 billion in 2Q17, a 1.5% decline as compared to $1.45 billion in 2Q16.
The US Specialized therapeutics business includes products from various therapeutic areas including eye care, medical aesthetics including skin care, facial aesthetics, plastic surgery and other products, ...
Various factors like the strong performance of key brands and the acquisition of LifeCell and other brands contributed to Allergan’s (AGN) revenue growth in 2Q17.